How will GINA influence participation in pharmacogenomics research and clinical testing?

Full Abstract

After a 13-year battle in Congress--longer than it took to map the human genome--the Genetic Information Nondiscrimination Act (GINA) was passed into law on 21 May 2008. Before its passing, Francis Collins, then director of the National Human Genome Research Institute, testified before the 110th Congress that the success of personalized medicine hinged on the passing of the legislation. How will GINA, which takes effect in 2009, influence participation in pharmacogenomic research and clinical testing?

Author information

Author/s: Dressler, L G (LG); Terry, S F (SF);

Affiliation: Division of Pharmaceutical Outcomes and Policy, Institute of Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA. ynn_dressler(-atsign-)unc.edu

Journal and publication information

Publication Type: Journal Article

Journal: Clinical pharmacology and therapeutics (Clin Pharmacol Ther), published in United States. (Language: eng)

Reference: 2009-Nov; vol 86 (issue 5) : pp 472-5

Dates: Created 2009/10/21; Completed 2009/11/04;

PMID: 19844223, status: MEDLINE (last retrieval date: 11/4/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.